Skip to main content
OpenTrials
Completed

NCT Number: NCT00757939

A Study to Assess Regional Cerebral Blood Flow as an Alzheimer's Disease Biomarker Compared to Positron Emission Tomography in Patients With Mild-to-Moderate Alzheimer's Disease and Cognitively Normal Elderly Subjects (Study MK-0000-068)(COMPLETED)

The aim of the study is to determine if regional cerebral blood flow, measured by dynamic arterial spin labeling (dASL), can be a biomarker for stage of Alzheimer's disease. The study is designed to be conducted in 2 parts in participants with mild to moderate Alzheimer's disease, and participants with normal cognition. Various imaging studies will be done using magnetic resonance imaging (MRI) and positron emission tomography (PET) along with neurocognitive assessments. Participants who meet the study-entry criteria will have up to 8 study visits. Repeat imaging studies may be required if the initial data are incomplete or un-interpretable. The maximum number of PET scans during the study will be limited to four.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Alzheimer's Disease Alzheimer Disease Brain Diseases Central Nervous System Diseases Dementia Mental Disorders Nervous System Diseases Neurocognitive Disorders Neurodegenerative Diseases Tauopathies

Age range

55 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

The prospective participant must meet, at least, all of the criteria below (among others determined by the study staff) to be eligible for study participation.

The participant:

  • Has mild-to-moderate Alzheimer's Disease (AD), OR is considered cognitively normal;
  • Has been on stable doses of any regularly used medications for 4 weeks prior to study start;
  • Must have been on a stable dose for 12 weeks prior to study start, of any medications taken for AD.

Exclusion criteria

If the prospective participant meets any of the criteria below (among others determined by the study staff) they will NOT be eligible for study participation.

The participant:

  • Is living in a nursing home or skilled nursing facility;
  • Has severe AD;
  • Cannot undergo MRI;
  • Cannot undergo PET scans;
  • Has a history of neurological or neurodegenerative disorders, other than AD within 2 years prior to study start;
  • Has taken Tacrine or anti-parkinsonian medications within 3 months of study start;
  • Has taken corticosteroids, blood thinners, narcotic analgesics, benzodiazepines, or certain antihistamines within 1 month of study start;
  • Initiates, discontinues, or changes the dose of any AD treatment during the study.

Treatment and study plan

MRI

Other

During the study all participants will have 4 total MRI scans: baseline, 1 week, 6 and 12 months.

FDG-PET

Other

2 to 4 PET scans will be done over 12 months, 2 planned and 2 more if data from any of these are un-interpretable

Primary outcomes

  1. Regional cerebral blood flow, as measured by dASL.

    Time frame: 1 week, 6 and 12 months

    Part I: regional cerebral blood flow, measured by dASL at Baseline and 1 week in AD participants and cognitively normal controls. Part II: regional cerebral blood flow, measured at 6 months and 12 months in AD participants and normal control participants.

Secondary outcomes

  1. Rate of cerebral glucose consumption, MRglc, as measured by fludeoxyglucose-PET (FDG-PET)

    Time frame: 12 months

    Regional cerebral rate of glucose consumption, MRglc, as assessed by FDG-PET will be measured at Baseline in (Part I) and at 12 months in (Part II), in AD participants and normal control participants.

  2. Resting state functional MRI blood-oxygen-level-dependent (fMRI BOLD) response

    Time frame: 1 week, 6 and 12 months

    The resting state fMRI BOLD (blood-oxygen-level-dependent) signal will be evaluated for 'Goodness-of-Fit' to the default mode network at Baseline, 1 week, and 6 and 12 months in AD participants and normal control participants.

Sponsors and collaborators

Lead sponsor

Merck Sharp & Dohme LLC

Industry

Registry information

Official study title

A Two-Part Cross-Sectional and Longitudinal Study to Assess Regional Cerebral Blood Flow by Dynamic Arterial Spin Labeling as an Alzheimer's Disease Biomarker as Compared to FDG-PET in Patients With Mild-to-Moderate Alzheimer's Disease and Cognitively Normal Elderly Subjects

Important dates

Study start
2008
Primary completion
2010
Study completion
2010
First posted
Sep 23, 2008
Registry last updated
Aug 11, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.